# A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

> **NCT02497235** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 11 (actual)

## Conditions studied

- Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

## Interventions

- **DRUG:** TAK-935
- **DRUG:** [18F]MNI-792 (tracer)

## Key facts

- **NCT ID:** NCT02497235
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497235, "A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02497235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*